What is Cutaneous Lupus Erythematosus (CLE)?
Cutaneous Lupus is Lupus in the skin. This can exist without Systemic Lupus.
CLE can cause redness, scaly rash on the skin, hair loss, blisters and skin discoloration. This type of Lupus is not only treated with oral medication but with topical medication too.
Breakthrough of Litifilimab
Litifilimab is an anti-BDCA2 antibody that is used to treat skin diseases. One of the clinical trials that are ongoing right now is the use of this medicine for CLE.
According to the phase 2 LILAC Study, this medicine reduces skin disease activity in Lupus patients. The study showed that patients with active CLE with or without secondary SLE manifestations baseline scores on the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity scale (CLASI-A) were significantly reduced at week 16 with litifilimab versus the placebo.
Moderate to severe CLE patients did not support the results. There is still a long run of testing and clinical trials for Litifilimab to further evaluate its efficacy and safety for CLE patients.
Otherwise, the good news is that it can relieve skin disease activity in patients with active CLE is already a good start.
To learn more about this research, visit the link below:
Do you have CLE? Comment in the comment section your experience and medications.
Comments